Navigation Links
OncoSec Medical to Present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in New York
Date:3/18/2013

SAN DIEGO, March 18, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced Dr. Adil Daud , chair of OncoSec's Melanoma Advisory Board, will present at the HemOnc Today Melanoma and Cutaneous Malignancies Meeting at the Hilton New York Hotel on Friday, March 22 at 2:25 PM ET.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

Dr. Daud will provide a presentation titled "Gene Therapy in Melanoma with pIL-12" and will review previously announced Phase I and II data from the ImmunoPulse clinical program in melanoma. More information can be found here: http://www.hemonctodaymelanoma.com/agenda.aspx#Fri

About the HemOnc Today Melanoma Meeting
The HemOnc Today Melanoma Conference will feature more than 20 renowned speakers and 200 colleagues who will discuss pertinent aspects of management and biology of melanoma and other cutaneous malignancies.

The two-day event will feature expert perspectives from renowned specialists who have advanced expertise in oncology, dermatology and cutaneous malignancies and will explain how you can apply the new research and advances presented to your own patients and practice.

About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surge
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) today ... USA , has obtained state sales licenses from ... been in close contact with the major nationwide retail ... own label specialty generic products sold through these nationwide ... According to IMS Health, the U.S. pharma ...
(Date:4/16/2015)... BEDFORD, Mass. , April 16, 2015 /PRNewswire/ ... an important cervical cancer screening study i ... , a peer-reviewed journal of the American Cancer ... Quest Diagnostics and the University of Pittsburgh Medical Center, supports ... screening, which recommend that women 30-65 years of ...
(Date:4/16/2015)... 2015 Today, Kenneth C. Frazier , chairman ... was elected chairman of the Board of the Pharmaceutical Research ... president and CEO John J. Castellani announced that ... New Officers Elected to PhRMA Board Frazier ... C. Read , chairman and CEO of Pfizer, Inc. Also ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
... Duska Therapeutics,Inc., (OTC Bulletin Board: DSKA), announced today that ... protocol for review under a Special,Protocol Assessment (SPA) procedure ... Subject to securing an ... prospective, double-blind, placebo-controlled and randomized Phase 3,clinical trial with ...
... NEW YORK, Nov. 20 Clinical data from a ... Symposium shows DVT,treatment with the Trellis(R) Peripheral Infusion System ... the blood clot in most,patients in about 20 minutes. ... called isolated pharmacomechanical thrombolysis, restores,blood flow more quickly and ...
Cached Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3
(Date:4/17/2015)... (PRWEB) April 17, 2015 Scientists ... a multicenter team of U.S. and Venezuelan researchers, ... yet in humans among an isolated tribe of ... Venezuela. Bacterial diversity in the Yanomami, previously unexposed ... be nearly double that of people living in ...
(Date:4/17/2015)... Calvary Hospital recently announced Timothy P. Barr will be ... May 11. The Fund directs all fundraising efforts in support ... J. Spinelli, who retired several months ago. , “We are ... the important work that the Fund does every year,” said ... expand and bring our signature care to people who need ...
(Date:4/17/2015)... NJ (PRWEB) April 17, 2015 ... in the posterior pituitary and thought to help mothers ... between couples. To further substantiate this, new studies performed, ... the journal, Nature, and reported by Medical News Today ... a powerful influence over maternal social behavior. The study ...
(Date:4/17/2015)... New York, NY (PRWEB) April 17, 2015 ... is formulated to polish and perfect facial ... Ecuadorian Ivory Palm seeds and blend of energizing ... dulling dead skin cells that cause breakouts and ... , Star Ingredients: , Ecuadorian Ivory Palm Seeds, ...
(Date:4/17/2015)... 17, 2015 According to the ... 50 million Americans suffer from all types of allergies, ... eye allergies. Thanks to comprehensive allergy testing that’s being ... ), there’s now a way to get recommended treatment ... “Allergy triggers, or allergens, can vary by region of ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3
... New England Journal of Medicine suggested that moderate drinking ... individuals. The study was conducted over a 12-year period ... osteopathic physicians and podiatrists, aged 40 to 75 years. ... frequency of drinking. ,The study showed that it ...
... A study which appeared in the clinical journal ... associated with a five-year risk of ocular hypertension, ... prevalence// of glaucoma, in Caucasians. The study was ... to 84, who received baseline assessments of refractive ...
... Cancer and Leukemia Group B (CALGB) and presented at ... the effectiveness of reducing the interval between successive doses ... rates in breast cancer// women. This study was conducted ... in the 1980s that suggested the value of increased ...
... cancer has been associated to many risk factors like ... consumption. Several earlier studies have linked alcohol to breast ... because smoking often accompanies drinking, researchers have not been ... ,Now, researchers from Cancer Research, UK, who included dozens ...
... American Medical Association published a recent comparative study done ... results from a telephone survey of people living in ... who were asked to name up to three stroke ... a similar survey conducted in 1995 to study the ...
... a recent study have found that people who take ... higher risk of developing gastrointestinal bleeding. The study which ... anti-depressant// users, who were compared for hospitalizations due to ... ,Researchers found people on selective serotonin reuptake inhibitors, or ...
Cached Medicine News:Health News:Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy" 2
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
... flow and minimize pain when performing ... BD Microtainer Quikheel Lancet. The simple ... providing a precise and consistent incision, ... its casing, helping to protect you ...
Medicine Products: